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ABSTRACT

EFFECTS OF CATHARANTHINE ON DOPAMINE RELEASE IN THE NUCLEUS
ACCUMBENS AND ETHANOL CONSUMPTION

Emily K. Baldwin
Neuroscience Department
Bachelor of Science

This thesis discusses the history of catharanthine and related compounds, and
their potential anti-addictive properties. Current research is exploring possible
mechanisms of these properties. Past studies have found catharanthine has effects on
neurons that project to the mesocorticolimbic system, an area implicated in addiction. We
have seen that catharanthine decreases evoked dopamine (DA) release but increases basal
DA release. This is the first study to investigate catharanthine’s effect on DA
transmission in vivo. Using microdialysis, we determined the effect of catharanthine on
DA in the nucleus accumbens of the striatum. This study determines the effect of
different doses of catharanthine, kinetics of catharanthine, and the effect of catharanthine
and ethanol injections. We also used the drink in the dark behavioral method to determine
if catharanthine decreased drinking behavior in mice.
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REVIEW OF CRITICAL LITERATURE
Impact of Alcohol Addiction on Society
The most prevalent substance use disorder is alcohol addiction (Degenhardt et al.,
2018). In 2019, the National Institute of Health reported that 14.1 million adults in
America suffered from alcohol use disorder (AUD). Those who suffer will continue to
use alcohol (also called ethanol or EtOH) despite its physical, social, and emotional
adverse consequences (NIH, 2020). As of 2015, there were over 90,000 alcohol related
deaths a year in the United States, including an average of 29 years of life lost per each
death (Esser et al., 2020). Alcohol abuse is the third leading cause of preventable death in
the United States. It is estimated that alcohol abuse costs the United States of America
over 250 billion dollars annually (CDC, 2015). AUD doesn’t only cause problems for the
individual but has adverse effects on a person’s family and social circle. Children of
alcoholics have higher rates of certain cognitive disorders and behavioral disorders
(Rothenberg et al., 2017). Unstable home environments for children of alcoholics lead to
many of these deficits (Park & Schepp, 2015). Acts of domestic violence and crime are
often associated with alcohol use (Quigley & Leonard, 2000).
Alcohol withdrawal symptoms include anxiety, headaches, nausea, sweating,
delirium, and seizures (Muncie et al., 2013). If chronically abusing alcohol, these make it
dangerous to abruptly quit drinking. Withdrawal symptoms are psychologically and
physiologically painful, making it hard to detox and further recover from AUD. A major
goal of research is to find better treatments for AUD.
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There are currently three FDA approved medications for treating AUD. Antabuse
inhibits the enzyme that metabolizes acetaldehyde, a byproduct of alcohol metabolism.
Excess acetaldehyde leads to adverse symptoms like dizziness, nausea, and an increased
heartrate. The idea behind Antabuse is that if drinking causes these unpleasurable
symptoms, people will not drink. For the same reason, the drug compliance for those
prescribed Antabuse is low (Hardt, 1992). Naltrexone is a mu opioid receptor antagonist,
blocking the euphoria associated with drinking (Sudakin, 2016). Acamprosate is
prescribed to reduce craving in AUD patients who have already detoxed from alcohol
(Mason, 2006). None of these treatments acts as a “cure” for AUD. Each has its merits
and its problems, which is why a goal for researchers is to find better pharmacological
treatments to help addicts.
Dopamine’s Role in Reward and Addiction
The mesocorticolimbic system is often called the reward circuit because of its
integral role in motivation and pleasure. It is naturally an important brain system, as it is
involved in vital behaviors like eating and drinking (Agmo et al., 1995). Our current
understanding of this system focuses on dopamine (DA) neurons from the ventral
tegmental area (VTA) projecting to the nucleus accumbens (NAc). The circuitry is much
more complicated than these two areas. This system gets inputs from many brain areas
and has many outputs. However, the current dogma of reward and addiction states that
increased DA release in the NAc signals pleasure (Gardner, 2011). Addictive drugs will
take over this circuitry. Drugs of abuse can increase DA to 10 times the levels associated
with natural rewards. Therefore, in this model of addiction drugs will be intensely
rewarding and lead to perseveration and addiction (Kalivas & Volkow, 2005).
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Dopamine is not only implicated in the pleasurable effects of alcohol and other
drugs, but also in the craving and withdrawal symptoms. While drugs will initially raise
DA levels, when the drug is gone, DA will fall to a level below the pre-drug baseline
level. The current theory states that this depletion of DA leads to the “craving” of a drug
and need to take a drug again to achieve higher dopamine levels (Koop, 2003). When it
comes to alcohol, this lowest point of DA is when the urge to drink is the strongest.
Indeed, chronic alcohol abusers have lower levels of baseline DA than non-addicts
(Volkow & Wang, 2007).
Catharanthine and Related Compounds
Ibogaine is a natural compound that comes from the root of the Tabernanthe
Iboga tree. Ibogaine may decrease craving and withdrawal symptoms (Maisonneuve &
Glick, 2003). Initial evidence for this in humans was anecdotal, with recreational
ibogaine users noting they didn’t desire other drugs they were addicted to (Lotsof, 2001).
Some animal studies have shown ibogaine may decrease self-administration of EtOH
(Rezvani et al., 1995), morphine (Glick, 2003), and cocaine (Cappendijk, 1993). Despite
some promising research, the side effects of ibogaine make it a less than ideal treatment
for addiction. In many patients ibogaine has induced tremors, cardiac arrhythmias, and
nausea. Ibogaine is also hallucinogenic and has led to weeks of mania in some patients
(Litjens, 2015).
Ibogaine belongs to a class of compounds called iboga alkaloids. Other
compounds in this family include coronaridine, 18-methoxycoronaridine (18-MC), and
catharanthine. Another name for these compounds is coronaridine congeners. These
compounds are promising research targets for addiction treatments with fewer side
3

effects (Maisonneuve & Glick, 2003). Ibogaine activates a variety of nicotinic
acetylcholine receptor (nAChR) subtypes and possibly NMDA receptors as well (Glick et
al., 2002). 18-MC and catharanthine bind more specifically to nAChRs than ibogaine
does with no NMDA activity. This is likely why they have fewer side effects. In fact,
catharanthine binds to α3β4 subtype nAChRs with much more specificity than any other
receptor type, where ibogaine also binds to α4β2 receptors (Arias, 2017). Catharanthine
also activates GABAa receptors, inducing a mild sedative effect (Arias et al., 2020).
Medial Habenula NAChRs and Anti-Addictive Properties
α3β4 receptors are mostly found in the medial habenula (MHb) (Grady et al.,
2009), as opposed to α4β2 receptors which are in many more brain areas. The medial
habenula has already been considered for its possible role in reward systems. The
habenula interacts with dopamine neurons to signal negative reward (Matsumoto &
Hikosaka, 2007). Many genes associated with addiction are expressed in the MHb
(Velasquez et al., 2014).
Inhibition of habenular α3β4 nAChRs have been implicated in the anti-addictive
effects of coronaridine congeners. Activity of nAChRs with α3 and β4 subunits have
been associated with the rewarding properties of nicotine (McCallum et al., 2012). Tonic
activity of these same neurons happens during nicotine withdrawal as well (Gorlich et al.,
2013). Antagonism of these receptors and decreased habenular ACh current reduce selfadministration of morphine, methamphetamine (Glick et al., 2002) and nicotine (Toll et
al., 2012). Knockout mice with no β4 subunits have reduced nicotine withdrawal
symptoms (Salas et al., 2004).
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Anatomically, MHb axons and project to the VTA (Sutherland, 1982) through the
fasiculus retroflexus (Nishikawa et al., 1986). When administered with no other
treatment, nicotine increases DA in the NAc. When 18-MC is injected directly in the
MHb, nicotine administration does not increase accumbal DA (McCallum et al., 2012).
Injection of α3β4 inhibitors into the MHb decreases drug self-administration, but
injection of these into the VTA does not (Glick et al., 2011). This shows that even when
there is no direct pharmacological effect on the mesocorticolimbic system, inhibition of
habenular nAChR activity somehow modulates neurotransmission in the reward pathway.
However, we do not know the mechanism through which this modulation happens.
Rationale and Hypotheses
While the exact anti-addictive mechanism of coronaridine congeners is still
unclear, their nAChR inhibition is likely the starting point. We know that a decrease of
α3β4 activity and ACh current is associated with decreased drug intake. Decreased
habenular nAChR activation can block the dopamine increase, withdrawal symptoms,
and rewarding effects involved with nicotine (McCallum et al., 2012). We also know the
MHb synapses on the VTA (Sutherland, 1982). This evidence combined suggests that
coronaridine congeners and other α3β4 antagonists inhibit MHb activation, which may
decrease neurotransmission to the VTA from this area. This would mean less activation
of VTA, and therefore less dopamine release on the NAc. More work is required to
determine if this idea is correct, and the exact receptors involved in the process.
Catharanthine inhibits habenular α3β4 receptors with high affinity and decreases
ACh current (Arias, 2017). Since many studies have shown that inhibition of α3β4
NAChRs and decreased ACh current can decrease self-administration of many drugs, so
5

catharanthine it has the potential to decrease alcohol self-administration. In fact, much of
the current research uses ibogaine or 18-MC to inhibit NAChRs and often low levels of
many α3β4 blockers have to be combined (Toll et al., 2012). Catharanthine has higher
specificity for habenular α3β4s than other coronaridine congeners, so it could be a better
target for an anti-addictive compound (Arias, 2017).
There are currently no published studies about catharanthine’s effects on DA
transmission. We understand catharanthine’s actions on habenular receptors and theorize
that this inhibition further inhibits dopamine release through MHb and VTA connections.
Thus, we decided to start looking at DA systems directly to see if this idea holds true. As
discussed, dopamine is an important signal for learning and reward. Our lab has
performed some preliminary work on catharanthine and dopamine, but until this thesis
there has been no in vivo work. Understanding catharanthine’s effect on dopaminergic
systems in a living rodent model can help us better understand it’s possible anti-addictive
effects. In addition to catharanthine’s effects alone, it will be interesting to determine if
catharanthine could block the DA increase expected with drugs of abuse.
It is also interesting to note that the sedative properties of catharanthine may also
factor into its use for alcohol withdrawal. Although not FDA approved for this purpose, it
is common for physicians to prescribe benzodiazepines and other sedative drugs to
alleviate the anxiety associated with alcohol withdrawal (Muncie et al., 2013).
Benzodiazepines have some dependence liability (Licata & Rowlett, 2008), but
catharanthine’s sedative effects utilize a benzodiazepine-independent mechanism (Arias
et al., 2020). While this GABAergic mechanism is not the focus of this thesis, it is a
factor to consider in interpreting behavioral results. Thus, we hypothesize that
6

catharanthine will modulate DA transmission similar to EtOH. Catharanthine may target
the same neural substrates as EtOH, serve to substitute for EtOH effects, and similar to
benzodiazaepines, ameliorate withdrawal from chronic EtOH without the side effects of
benzodiazepines.
The inhibitory effect of catharanthine on habenular α3β4 nAChRs could be
important when it comes to alcohol withdrawal. Since α3β4 nAChRs seem to be required
for withdrawal of some drugs (Gorlich et al., 2013) and α3β4 knockout mice have
reduced withdrawal (Salas et al., 2004)—catharanthine could help alleviate withdrawal
symptoms with its cholinergic mechanisms. Knowing catharanthine decreases cholinergic
activity in the MHb, an area associated with negative reward, means it could also inhibit
negative reward involved with withdrawal.
PRELIMINARY WORK
Catharanthine
Preliminary studies in our lab have shown that catharanthine enhances basal DA
release but reduces evoked DA release ex vivo. Figure 1 shows the effects of 30 μM
catharanthine on basal and evoked DA release. Catharanthine enhances basal (Fig. 1 A,
B) and reduces (Fig. 1 C, D) evoked DA release ex vivo in a dose dependent manner This
was accomplished using fast scan cyclic voltammetry in the NAc of drug-naïve mice.
However, catharanthine oxidizes at the same voltage as DA. However, this is a confound
in the basal DA release studies, but not in evoked DA release as the evoked values come
from subtracting from baseline values. This makes the data on basal DA release hard to
interpret. We sought to determine the mechanism underlying catharanthine inhibition of
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evoked DA release. As catharanthine effects appear similar to EtOH, we investigated
diverse pharmacological tools to dissect catharanthine effects similar to what we have
done with EtOH. We tested cadmium (CAD), NAChR blocker DHBE, the D2R blocker
eticlopride (ETIC), mecamylamine (MECA), the non-α7 nAChR blocker, the α6
conotoxin MII, the mu-opioid receptor
antagonist naltrexone (NALT), or the
GABAR blocker picrotoxin (PIC)
affected catharanthine inhibition of
evoked DA release in the NAc (Fig.
1D). None of these well-known and
relevant drugs affected catharanthine
inhibition of evoked DA release but

Figure 1: Effects of catharanthine on basal DA release, carbon fiber
electrode oxidation, and evoked DA release ex vivo. (A,B)
Catharanthine (30 M) increased basal DA release, which was blocked
by the -conotoxin 6-nAChR antagonist MII, suggesting that its
effects are mediated via cholinergic interneuron modulation of DA
release at terminals in the NAc. (C,D) Indeed, catharanthine actually
decreased evoked DA release, wherein baseline levels are background
subtracted. MII had no effect on catharanthine inhibition of evoked DA
release. (E) Pharmacology of catharanthine effects on evoked DA
release. Although some drugs had effects on release alone, none of
them except the nAChR antagonist mecamylamine blocked
catharanthine inhibition of evoked DA release in the NAc (in box).
CAD=cadmium;
Etic=eticlopride;
MECA=mecamylamine;
NAL=naltr

MECA, suggesting that nAChRs are
involved in catharanthine effects on
DA release similar to what has been
shown on behavioral measures by other
researchers. Given the confound of
direct catharanthine effects on
voltammetric recordings, it is important
to evaluate its effects in vivo with
methods other than voltammetry to
establish the physiological relevance
and justification for studying its effects
exone; PIC=picrotoxin
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on EtOH consumption, especially
since catharanthine oxidizes at
similar potentials as DA. In
addition, it is hypothesized that
catharanthine’s enhancement of DA
release will reduce the rewarding
properties of EtOH in naïve mice
and the adaptive properties of EtOH
dependent mice.
Ethanol

Figure 2: Effects of ethanol on dopamine release in vivo using
microdialysis and HPLC. Ethanol enhanced DA release at dose levels
0.5-4.0 g/kg. However, the kinetics differed across doses with a delay
in enhancement at 4.0 g/kg. The most consistent effect was seen at 2.0
g/kg.

Previous lab work has
determined that 2.0 g/kg EtOH maximally enhances DA in the core of the nucleus
accumbens. Figure 2 shows the effect of ethanol on DA release at ethanol doses.

METHODS
Microdialysis
Male VGAT-Cre/GAD67 mice were anesthetized using isoflurane. In a non-survival
surgery, a hole was drilled to the NAc (+2.0 AP, -.9 ML, -3.6 DV from bregma) and a
microdialysis probe (MD-2211 1mm Membrane Probe, BASi Instruments, West
Lafayette, IN, USA) was inserted and held in place. During the experiment, artificial
cerebrospinal fluid (aCSF) flowed at a rate of 2 μL/min. aCSF went through the probe
and through the membrane, so dialysate samples contained neurotransmitters released in
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the NAc. Dialysate samples were collected every 20 minutes. All catharanthine doses
were dissolved in a vehicle of 95% saline (9% NaCl) solution and 5% Tween 80.
Catharanthine Dose Response
Samples were collected as a baseline for 40 minutes. A 5 mg/kg dose was injected
at time zero and dialysate samples were collected for another 40 minutes. After 40
minutes, the 10 mg/kg dose was injected. The 20 and 50 mg/kg doses were also collected
for 40 minutes after the previous dose.
Catharanthine Time Course
Samples were collected as a baseline for 60 minutes. A 10 mg/kg dose was
injected at time zero and dialysate samples were collected for two hours post-injection.
Catharanthine + EtOH experiments
In the catharanthine + ethanol experiments, baseline samples were collected for
60 minutes. A 10 mg/kg dose of catharanthine was injected at time zero. 20 minutes later,
2.0 g/kg ethanol was injected. Samples were collected for another 100 minutes post EtOH
injection.
HPLC
Samples were evaluated using high pressure liquid chromatography with
electrochemical detection (HPLC-ECD). Analysis of DA was done using an Ultimate
3000 system (Thermo Fischer Scientific, Waltham, MA, USA) connected to a
Coulochem III electrochemical detector (Thermo Scientific, Waltham, MA, USA) with
an Acclaim RSLC Polar Advantage II Column to perform separations and the
10

Chromeleon computer program. The mobile phase consisted of 150 mM sodium
dihydrogen phosphate, 4.76 mM citric acid, 3 mM sodium dodecyl sulfate, 50 M
EDTA, 15% HPLC grade acetonitrile, 10% HPLC grade methanol, and 75% HPLC grade
water. Mobile phase was adjusted to pH 5.6 using NaOH. This mobile phase recipe
comes from Thermo Scientific’s “Chromatography for Neuroscience Applications
Notebook” for Monoamines and Metabolites.”
Drink in the Dark
Twelve adult VGAT-Cre/GAD 67 were used for this procedure. Drink in the dark
(DID) experiments took place during the mice’s dark cycle, 3 hours after lights turned
off. During the DID procedure, mice were caged individually. In the time in between
drinking, mice were housed with one other cage mate in the same experimental group as
them. At the beginning of the procedure, bottles of 16% ethanol were put in the cage. On
days 1-3, mice were allowed to drink for two hours. On day 4, mice drank for 4 hours to
better simulate binge drinking and a max amount of ethanol drank. During week 2, mice
were injected with either catharanthine in vehicle or vehicle only. There were six mice in
each experimental group. Catharanthine injections were 10 mg/kg, and vehicle injections
were an equal volume per body weight ratio. Injections were done intraperitoneally 20
minutes before the drinking protocol. On days 5-7, mice drank for two hours and on day
8 mice drank for 4 hours. Bottles were weighed before and after. Differences were
measured in grams. Three bottles were also placed in empty cages and measured to
control for the bottles leaking. The average of leak control was subtracted from the
amount drank in all calculations.
RESULTS
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Catharanthine injected on its
own increased basal DA. The initial
dose curve micro dialysis experiments
(n=9; Figure 3) showed that the 5
mg/kg, 10 mg/kg, 20 mg/kg, and 50
mg/kg doses all enhance DA release
in the NAc in vivo as recorded with
microdialysis/HPLC. The maximal
effect was around 10 mg/kg,

Figure 3: Effect of different concentrations of catharanthine on
basal DA release recorded with microdialyis in vivo.
Catharanthine markedly enhanced 5mg/kg, 10 mg/kg, 20 mg/kg,
and 50 mg/kg catharanthine on basal DA release.

increasing basal DA to around 250%
of baseline. This agrees with previous voltametric readings showing catharanthine
increases basal DA. Based on this data, we decided to continue experiments using the 10
mg/kg dose. Since the 10, 20, and 50 mg/kg doses showed similar effects, using the 10
mg/kg was desirable to reduce the injection volume used in mice.
Further kinetics experiments (n=3) showed that catharanthine’s enhancement of
basal DA occurred 20 minutes post-injection and recovered to baseline in 20 minutes
(data not shown). Thus, further microdialysis and behavior experiments involve
catharanthine treatment 20 minutes before ethanol treatment.
In the next experiments, 10 mg/kg catharanthine was injected. Twenty minutes
later, a 2 g/kg dose of ethanol was injected. Ethanol is normally expected to increase
basal dopamine. Although preliminary (n=4), it appears that catharanthine inhibits the
typical enhancement of DA release by EtOH (Figure 4).
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We performed DID experiments that aimed to see if catharanthine would decrease
drinking behavior in mice. Mice were separated into two groups of six mice each. Three
hours into the dark cycle they were
allowed to drink EtOH. Mice drank for a
week previous to any injections, and for
week two they were injected with
catharanthine or vehicle twenty minutes
before drinking. The results of this
experiment were inconclusive.
Catharanthine decreased week 2 drinking

Figure 4: Catharanthine may reduce ethanol effects on
DA release in vivo. Ethanol (2.0 g/kg) moderately
enhances DA release in 20 min (n=7) with some recover
over 1.5 hrs. Administration of Catharanthine (10 mg/kg)
20 min before EtOH reduced the ability of EtOH to
enhance DA release (n=4).

in some mice, but not in others (Figure 5).
Vehicle also decreased drinking in some
mice, so it is possible some effects were
due to timing and previous ethanol exposure.

CONCLUSION
This in vivo work, along with
previous ex vivo work, shows that
catharanthine increases basal dopamine
in the nucleus accumbens. This effect on
its own shows that catharanthine is
psychoactive in some way and has some
effect on the reward pathway. It is

Figure 5: Effects of 10 mg/kg catharanthine on EtOH
consumption in the DID procedure. Perhaps due to EtOH leak
from the bottle, some mice consumed large quantities of EtOH
the first week. Regardless, although drinking stabilized
somewhat, there was no significant difference between
vehicle and catharanthine treatment.
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important to note that depending on the size of this effect in relation to other drugs or
rewards, catharanthine may or may not be pleasurable itself. That is a topic of future
study for our lab.
While a DA increase is expected in response to alcohol, catharanthine can block
that. This is an important find in finding a possible mechanism for catharanthine’s antiaddictive properties. Catharanthine and EtOH are interacting in some way, but we do not
currently know how. In future research, we hope to use blockers for specific receptors in
vivo to study the mechanisms catharanthine may use to modulate DA transmission.
Specifically, we want to see how catharanthine’s modulation of α3β4 nAChRs modulates
dopamine transmission. This could also help us better understand catharanthine’s effect
when combined with EtOH.
Our DID data didn’t tell us much about catharanthine’s effect on drinking
behavior. However, this may be due to an error in experiment design. Our DID
conditions likely did not simulate alcohol dependence like we wanted it to. Our mice
drank freely but were not ethanol dependent. It takes 2-3 cycles of DID to produce
dependence, shown by progressively enhanced consumption of ethanol. Since we are
studying catharanthine as a possible treatment for patients going through withdrawal, this
specific experiment probably can’t say much about catharanthine’s efficiency. So, while
this data was useful to see if catharanthine did do anything to baseline drinking levels, the
fact it didn’t doesn’t necessarily mark the end of catharanthine DID studies. The next step
will be to make mice dependent through chronic EtOH injections or EtOH chambers and
then see if catharanthine effects drinking in a dependent group. These experiments cannot
be included in this thesis due to time constraints.
14
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